Home » Healthcare » Pharmaceuticals » Myelodysplastic Syndrome (MDS) Treatment Drugs Market

Myelodysplastic Syndrome (MDS) Treatment Drugs Market By Drug Class (Hypomethylating Agents, Immunomodulatory Drugs, Growth Factors) – Growth, Future Prospects And Competitive Analysis, 2017 – 2025

Summary
Table Of Content

Market Insights

Myelodysplastic syndrome (MDS) is a type of cancer that is considered a group of blood and bone marrow disorders and involves the production of abnormal and immature blood cells. It is anticipated that the MDS treatment drugs market will show significant market growth over the forecast period due to the rising prevalence of MDS, an increase in spending in the healthcare system, growing investments in R&D for MDS treatment, and the strong presence of ideal pipeline drugs. The expected launch of late-stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069, and rigosertib is anticipated to drive significant market growth over the forecast period of 2017–2025.

The report titled “Myelodysplastic Syndrome (MDS) Treatment Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” covers in-depth data related to the MDS treatment drug market. The report covers an overall analysis related to market segments based on drug class (hypomethylating agents, immunomodulatory drugs, growth factors, and others) and different geographies.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Based on geographical distribution, the global myelodysplastic syndrome (MDS) treatment drug market covers the following:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

The geography segmentation in the report provided market situation and data forecasts for all regional markets.

Along with market size data, this report includes qualitative information tools for in-depth analysis of market situations. Market information, such as drivers, challenges, and opportunities, about MDS treatment drugs is also included in the report. To provide overall information regarding the expected launch of MDS therapeutics, a pipeline analysis of late-stage MDS treatment drugs is included in the report. The competitive landscape of key manufacturers and a company profiles section are included in the report to provide general information regarding market players’ positions and growth. Furthermore, this report provides information on mergers and acquisitions among the key players in the MDS treatment drug market.

Based on drug type, the global myelodysplastic syndrome (MDS) treatment drugs market is segmented as follows:

Hypomethylating Agents

Azacitidine
Decitabine

Immunomodulatory Drugs

Lenalidomide

Growth Factors

Epoetin Alfa
Darbepoetin Alfa
Filgrastim

Other

Cytarabine
Daunorubicin
Idarubicin
Topotecan
Fludarabine

MDS is characterized by the production of immature blood cells that are unable to function properly and die earlier than normal blood cells. MDS treatment is typically given to slow disease progression and manage MDS symptoms. Although various forms of drugs are used in the treatment of MDS, currently, only three drugs are approved by the US FDA, which include azacitidine, decitabine, and lenalidomide. A higher number of unmet needs, the strong presence of pipeline molecules, and the growing pool of the geriatric population are the prime factors that influence the growth of the MDS treatment drug market. In recent years, demand for hypomethylating agents has been the highest on the market due to their proven effectiveness in low as well as high-risk MDS patients.

Since 2006, no single drug has been approved by the US FDA for the treatment of MDS. The expected launch of late-stage pipeline molecules such as JNJ-63935937 (Janssen Biotech), MLN-4924 (Takeda Pharmaceutical), NSC 39069 (Medac), and rigosertib (Onconova Therapeutics) would drive lucrative market growth during the forecast period of 2017 to 2025.

In the base year 2016, North America held the largest market share for myelodysplastic syndrome treatment drugs and is anticipated to continue to show dominance over the forecast period. The United States is the largest market in North America. Some factors, such as an increase in the prevalence of MDS, a better early diagnosis rate, a higher cost of treatment medication, high treatment awareness, and favorable reimbursement policies by private organizations and government agencies, favor the dominance of the North American market.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

According to the American Cancer Society, in the United States, MDS occurs at a rate of 4.8 cases per 100,000 people; every year, approximately 13,000 people are diagnosed with MDS. The swift adoption of novel medications and the expected launch of late-stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069, and rigosertib would further assist the MDS treatment drug market in the United States. On the other hand, the MDS treatment drugs market in the Asia Pacific is set to tap significant growth during the forecast period due to the growing number of geriatric populations, increasing patient awareness, and developing healthcare infrastructure.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Portraiture
2.1.1. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2016 (US$ Mn)
2.1.2. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3. Myelodysplastic Syndrome (MDS) Treatment Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Pipeline Analysis of Myelodysplastic Syndrome (MDS) Treatment Drugs
4.1. Overview
4.2. Pipeline Analysis of Phase 3 Drugs
4.3. Tabular Presentation of Phase 1 and Phase 2 Drugs

Chapter 5. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition, by Drug Class, 2016
5.3. Hypomethylating Agents
5.3.1. Azacitidine
5.3.2. Decitabine
5.4. Immunomodulatory Drugs
5.4.1. Lenalidomide
5.5. Growth Factors
5.5.1. Epoetin Alfa
5.5.2. Darbepoetin Alfa
5.5.3. Filgrastim
5.6. Others
5.6.1. Cytarabine
5.6.2. Daunorubicin
5.6.3. Idarubicin
5.6.4. Topotecan
5.6.5. Fludarabine

Chapter 6. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.2.1. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.2. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. China
6.4.2.2. Japan
6.4.2.3. Rest of APAC
6.5. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025
6.6.1. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.2. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Bayer AG
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Drug Class Portfolio
7.1.4. Key Developments
7.2. Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
7.3. Celgene Corporation
7.4. Cell Therapeutics, Inc.
7.5. Daiichi Sankyo Company, Ltd.
7.6. Incyte Corporation
7.7. Janssen Biotech, Inc.
7.8. MedImmune, LLC (AstraZeneca)
7.9. Millennium Pharmaceuticals (Takeda Pharmaceutical)
7.10. Novartis AG
7.11. Onconova Therapeutics, Inc.
7.12. Pfizer, Inc.
7.13. Taiho Pharmaceutical (Otsuka Holdings)
7.14. Other Notable Players

List of Figures

FIG. 1 Myelodysplastic Syndrome (MDS) Treatment Drugs: Market Segmentation
FIG. 2 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Azacitidine Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Decitabine Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Lenalidomide Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Epoetin Alfa Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Darbepoetin Alfa Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Filgrastim Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Cytarabine Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Daunorubicin Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Idarubicin Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Topotecan Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Fludarabine Market, 2015 – 2025 (US$ Mn)
FIG. 17 U.S. Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Canada Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 U.K. Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 Germany Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 Japan Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 China Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Brazil Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 Mexico Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 28 GCC Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Myelodysplastic Syndrome Market Portraiture
TABLE 2 Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2015 – 2025 (US$ Mn)

Frequently Asked Question:

What is the size of Myelodysplastic Syndrome Treatment Drugs Market?

The market for Myelodysplastic Syndrome Treatment Drugs Market is expected to reach USD$ XX Mn in 2025.

What is the Myelodysplastic Syndrome Treatment Drugs Market CAGR?

The Myelodysplastic Syndrome Treatment Drugs Market is expected to see significant CAGR growth over the coming years, at 9.5%.

What is the Forecast period considered for Myelodysplastic Syndrome Treatment Drugs Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Myelodysplastic Syndrome Treatment Drugs Market?

The base year of this report is 2016.

Who are the major players in this market?

Bayer AG, Celator Pharmaceuticals (Jazz Pharmaceuticals plc.),Celgene Corporation, Cell Therapeutics, Inc.,Daiichi Sankyo Company, Ltd., Incyte Corporation. are some of the major players in market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –